{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:54:48Z","timestamp":1760550888583,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jfma.2019.07.003","type":"journal-article","created":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T16:12:15Z","timestamp":1563639135000},"page":"1466-1470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan"],"prefix":"10.1016","volume":"118","author":[{"given":"Feng-Ming","family":"Tien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hong","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Hau","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2019.07.003_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/bjc.2012.228","article-title":"Long-term survival after treatment for Hodgkin's disease (1973\u20132002): improved survival with successive 10-year cohorts","volume":"107","author":"Bessell","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jfma.2019.07.003_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/phar.1170","article-title":"Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate","volume":"33","author":"Newland","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jfma.2019.07.003_bib3","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol \u2013 Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.jfma.2019.07.003_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1620\/tjem.224.151","article-title":"Clinicopathological features of malignant lymphoma in Japan: the Miyagi study","volume":"224","author":"Miura","year":"2011","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.jfma.2019.07.003_bib5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfma.2016.11.006","article-title":"Lymphoma in Taiwan: Review of 1347 neoplasms from a single institution according to the 2016 revision of the world health organization classification","volume":"116","author":"Chuang","year":"2017","journal-title":"J Formosan Med Assoc Taiwan yi zhi"},{"key":"10.1016\/j.jfma.2019.07.003_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification","volume":"138","author":"Sun","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jfma.2019.07.003_bib7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/imj.13415","article-title":"Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed\/refractory CD30 positive lympho-proliferative disorders: a single centre experience","volume":"47","author":"Mediwake","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.jfma.2019.07.003_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdi003","article-title":"Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)","volume":"16","author":"Josting","year":"2005","journal-title":"Ann Oncol \u2013 Offic J Eur Soc Med Oncol"},{"key":"10.1016\/j.jfma.2019.07.003_bib9","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J Clin Oncol \u2013 Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.jfma.2019.07.003_bib10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdx791","article-title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"29","author":"Herrera","year":"2018","journal-title":"Ann Oncol \u2013 Offic J Eur Soc Med Oncol"},{"key":"10.1016\/j.jfma.2019.07.003_bib11","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2019.07.003_bib12","volume":"128","author":"Garcia-Sanz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2019.07.003_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461930275X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461930275X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:39:46Z","timestamp":1760539186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966461930275X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S092966461930275X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2019.07.003","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2019.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}